Low Compliance Bladder

Categories: Nephrological diseases

Aliases & Classifications for Low Compliance Bladder

MalaCards integrated aliases for Low Compliance Bladder:

Name: Low Compliance Bladder 12 15 71
Hyperactivity of Bladder 12
Hypertonicity of Bladder 12
Low Bladder Compliance 12
Hypertonic Bladder 12
Overactive Bladder 71


External Ids:

Disease Ontology 12 DOID:12144
ICD9CM 34 596.52
SNOMED-CT 67 9009001
UMLS 71 C0489967 C0878773

Summaries for Low Compliance Bladder

MalaCards based summary : Low Compliance Bladder, also known as hyperactivity of bladder, is related to neurogenic bladder and cystitis, and has symptoms including dysuria, prostatism and urgency of micturition. An important gene associated with Low Compliance Bladder is P2RX3 (Purinergic Receptor P2X 3), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and G alpha (s) signalling events. The drugs Propiverine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and spinal cord.

Related Diseases for Low Compliance Bladder

Graphical network of the top 20 diseases related to Low Compliance Bladder:

Diseases related to Low Compliance Bladder

Symptoms & Phenotypes for Low Compliance Bladder

UMLS symptoms related to Low Compliance Bladder:

dysuria, prostatism, urgency of micturition, lower urinary tract symptoms

Drugs & Therapeutics for Low Compliance Bladder

Drugs for Low Compliance Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Propiverine Approved, Investigational Phase 4 60569-19-9 4942
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Doxazosin Approved Phase 4 74191-85-8 3157
Citalopram Approved Phase 4 59729-33-8 2771
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Acetaminophen Approved Phase 4 103-90-2 1983
Meperidine Approved Phase 4 57-42-1 4058
Tenoxicam Approved Phase 4 59804-37-4 5312154
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
Belladonna Approved, Experimental Phase 4
Baclofen Approved Phase 4 1134-47-0 2284
Opium Approved, Illicit Phase 4 8008-60-4
23 Acetaminophen, hydrocodone drug combination Phase 4
24 Adrenergic alpha-Antagonists Phase 4
25 Mitogens Phase 4
26 Adrenergic Antagonists Phase 4
27 Adrenergic alpha-1 Receptor Antagonists Phase 4
28 Anticonvulsants Phase 4
29 Bromides Phase 4
30 Analgesics Phase 4
31 Estradiol 17 beta-cypionate Phase 4
32 Estradiol 3-benzoate Phase 4
33 Narcotics Phase 4
34 Opiate Alkaloids Phase 4
35 Analgesics, Opioid Phase 4
36 Antihypertensive Agents Phase 4
37 Serotonin Receptor Agonists Phase 4
38 Serotonin Uptake Inhibitors Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Antipyretics Phase 4
41 5-alpha Reductase Inhibitors Phase 4
42 Trospium chloride Phase 4 10405-02-4
43 Antitubercular Agents Phase 4
44 Hormones Phase 4
45 Hormone Antagonists Phase 4
46 Estrogens Phase 4
47 Estrogens, Conjugated (USP) Phase 4
48 Anti-Bacterial Agents Phase 4
49 Neuromuscular Blocking Agents Phase 4
50 Tolterodine tartrate Phase 4 124937-52-6

Interventional clinical trials:

(show top 50) (show all 680)
# Name Status NCT ID Phase Drugs
1 Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial Unknown status NCT01423838 Phase 4 Solifenacin;Oxybutynin
2 Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial Unknown status NCT03412513 Phase 4 Mirabegron;Placebo
3 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men Unknown status NCT02361502 Phase 4 mirabegron;placebo
5 Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study Unknown status NCT01876186 Phase 4 Solifenacin for 12 weeks;Solifenacin for 24 weeks
6 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
7 The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
8 A Combined Treatment Program for the Symptoms of Urinary Urgency and Frequency With Toviaz and Premarin Vaginal Cream Unknown status NCT01613170 Phase 4 Toviaz;Premarin;Placebo cream
9 Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
10 The Applicability of the OAB Assessment Tool for Evaluation of Treatment Efficacy of Overactive Bladder. Unknown status NCT00313924 Phase 4 DETRUSITOL
11 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
12 Efficacy of Peri-trigonal Onabotulinumtoxin Injections in the Treatment of Refractory Idiopathic Detrusor Overactivity (IDO): A Single-blind, Randomised Controlled Trial Comparing Peri-trigonal Injections vs Injection of the Bladder Body. Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
13 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
14 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
15 Randomized Pilot Study on the Treatment of Mixed Urinary Incontinence: Pharmacological Treatment (Tolterodine SR) vs Surgery With Tension Free Vaginal Tape Unknown status NCT00523068 Phase 4 Tolterodine
16 Overactive Bladder Symptom Scores (OABSS) Responsiveness Before and After Anticholinergic Treatment in Women With Overactive Bladder (OAB) Completed NCT02667470 Phase 4 Solifenacin
17 Phase IV Study to Evaluate the Efficacy and Safety Imidafenacin Versus Fesoterodine in Patients With Overactive Bladder Completed NCT01578304 Phase 4 Imidafenacin;Fesoterodine
18 Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX) Completed NCT00224146 Phase 4 oxybutynin transdermal delivery system (Oxytrol(r))
19 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder Completed NCT01945489 Phase 4 Normal saline
20 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Completed NCT02216214 Phase 4 Mirabegron;Placebo
21 URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4 solifenacin succinate (VESIcare);placebo
22 Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder Completed NCT00127270 Phase 4 Darifenacin;Darifenacin
23 A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB) Completed NCT02138747 Phase 4 Mirabegron;Tolterodine ER
24 VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients Completed NCT00431041 Phase 4 solifenacin;oxybutynin immediate release
25 Overactive Bladder Innovative Therapy Trial Completed NCT00448175 Phase 4 Tolterodine
26 Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms Completed NCT00771264 Phase 4
27 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
28 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder Completed NCT00171184 Phase 4 Darifenacin;Placebo
29 An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms Completed NCT02715024 Phase 4 Tamsulosin;Solifenacin
30 A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder. Completed NCT00928070 Phase 4 Fesoterodine;Placebo
31 A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine. Completed NCT01302067 Phase 4 Fesoterodine 8mg;Fesoterodine 4mg;Placebo
32 Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study Completed NCT01533597 Phase 4 Solifenacin;Solifenacin plus Tamsulosin
33 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients Completed NCT02601287 Phase 4
34 A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC). Completed NCT00143377 Phase 4 tolterodine SR, overactive bladder
35 A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Completed NCT02468375 Phase 4 mirabegron 50mg
36 Multi-site, Randomized, Opened and Controlled Comparison Study on the Effectiveness and Safety of Solifenacin Succinate Tablets and Solifenacin Succinate Tablets + Estrogen for Overactive Bladder in the Post-menopausal Women Completed NCT01833663 Phase 4 Solifenacin Succinate Tablets;Estrogen
37 A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy Completed NCT00366002 Phase 4 Darifenacin
38 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed NCT01089751 Phase 4 trospium chloride;placebo
39 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial Completed NCT01178827 Phase 4 trospium chloride;oxybutynin IR;oxybutynin IR placebo
40 A Multi-Centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder. Completed NCT00137397 Phase 4 Tolterodine ER;Placebo
41 A Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of Any Alpha Blocker Monotherapy and Any Alpha Blocker Plus Solifenacin in Men With Residual Overactive Bladder Symptoms of Urinary Frequency and Urgency With/Without Urgency Incontinence After Previous Monotherapy With Any Alpha Blocker Completed NCT00699049 Phase 4 Alpha blocker;placebo;solifenacin
42 A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency. Completed NCT00911937 Phase 4 Fesoterodine;Placebo
43 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Completed NCT00932022 Phase 4 Trospium Chloride, Extended Release (XR)
44 A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder. Completed NCT00798434 Phase 4 Placebo;Fesoterodine fumarate
45 A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures. Completed NCT00852696 Phase 4 Solifenacin
46 Comparison of the Effect of Flexible Dosage of Solifenacin Succinate Between Patients Who Have Frequent Micturition With and Without Urgency Completed NCT00979472 Phase 4 Solifenacin
47 A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER). Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
48 A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO) Completed NCT02092181 Phase 4 Mirabegron;Placebo
49 An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction Completed NCT00605319 Phase 4 Toviaz (Fesoterodine)
50 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna

Search NIH Clinical Center for Low Compliance Bladder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Genetic Tests for Low Compliance Bladder

Anatomical Context for Low Compliance Bladder

MalaCards organs/tissues related to Low Compliance Bladder:

Prostate, Testes, Spinal Cord, Brain, Smooth Muscle, Heart, Skin

Publications for Low Compliance Bladder

Articles related to Low Compliance Bladder:

(show top 50) (show all 6144)
# Title Authors PMID Year
Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord. 54 61
20335487 2010
Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. 61 54
19367641 2010
Augmented bladder urothelial polyamine signaling and block of BK channel in the pathophysiology of overactive bladder syndrome. 54 61
19812367 2009
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. 61 54
18472208 2009
Identification of large conductance calcium activated potassium channel accessory beta4 subunit in rat and mouse bladder smooth muscle. 61 54
19447431 2009
Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. 54 61
19220267 2009
Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. 61 54
19089891 2009
Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. 54 61
18489524 2008
Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. 54 61
18400272 2008
Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. 54 61
17892634 2007
GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. 54 61
17626794 2007
Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. 61 54
17155980 2007
Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. 54 61
17309345 2007
Beta3-adrenoceptors in urinary bladder. 61 54
17600372 2007
The promise of beta3-adrenoceptor agonists to treat the overactive bladder. 61 54
17011390 2006
Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. 61 54
16879488 2006
Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). 54 61
16517051 2006
Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. 54 61
16470209 2006
Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. 54 61
16323980 2005
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. 61 54
16096831 2005
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. 61 54
16100298 2005
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. 54 61
15839920 2005
Darifenacin: in the treatment of overactive bladder. 54 61
15493952 2004
Beta3-adrenoceptors in human detrusor muscle. 61 54
12007519 2002
Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. 61 54
11412212 2001
Melanosis of the bladder: A rare diagnosis. 61
32547928 2020
Stimulation of atypical cannabinoid receptor GPR55 abolishes the symptoms of detrusor overactivity in spontaneously hypertensive rats. 61
32360768 2020
Presence of leucocytes in prostatic secretions correlates with the severity of lower urinary tract symptoms. 61
32352587 2020
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction. 61
32259514 2020
TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder. 61
32332112 2020
Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications. 61
32452995 2020
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). 61
31718957 2020
Re: Effects of Biofeedback-Based Sleep Improvement Program on Urinary Symptoms and Sleep Patterns of Elderly Korean Women with Overactive Bladder Syndrome. 61
32293954 2020
Draft Genome Sequence of Actinomyces neuii UMB1295, Isolated from the Female Urinary Tract. 61
32499345 2020
Draft Genome Sequence of Staphylococcus epidermidis UMB8493, Isolated from the Female Urinary Tract. 61
32499349 2020
Re:Shi H, Chen H, Zhang Y, Cui Y. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials. Neurourology and Urodynamics. 2020. 61
32531071 2020
A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study. 61
31977308 2020
The impact of microalbuminuria on overactive bladders: Results from a community-based four-year longitudinal study in Japan. 61
32460389 2020
Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. 61
32540299 2020
Use of Botulinum Toxin in the Genitourinary System. 61
32562059 2020
Effect of darifenacin on fecal incontinence in women with double incontinence. 61
32542466 2020
Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms. 61
32259358 2020
Enduring impact of childhood adversity on lower urinary tract symptoms in adult women. 61
32368829 2020
Neural pathway of bellows response during SNM treatment revisited: Conclusive evidence for direct efferent motor response. 61
32484961 2020
Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation. 61
32548938 2020
A Multicenter Retrospective Cohort Study Comparing Urethral Diverticulectomy with and without Pubovaginal Sling. 61
32504566 2020
Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. 61
32383533 2020
Correlating Patient Anxiety with Urinary Symptoms Before and After Holmium Laser Enucleation of the Prostate. 61
32394722 2020
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. 61
32519241 2020

Variations for Low Compliance Bladder

Expression for Low Compliance Bladder

Search GEO for disease gene expression data for Low Compliance Bladder.

Pathways for Low Compliance Bladder

Pathways related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 11.5 PDE7A NPS ADRB3
Show member pathways
Show member pathways

GO Terms for Low Compliance Bladder

Cellular components related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon terminus GO:0043679 9.16 CHRM3 CHRM2
2 asymmetric synapse GO:0032279 8.96 CHRM3 CHRM2
3 integral component of presynaptic membrane GO:0099056 8.8 P2RX3 CHRM3 CHRM2

Biological processes related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 PDE7A PDE5A P2RX3 CHRM3 CHRM2 ADRB3
2 G protein-coupled receptor signaling pathway GO:0007186 9.65 PDE7A NPS CHRM3 CHRM2 ADRB3
3 chemical synaptic transmission GO:0007268 9.58 P2RX3 CHRM3 CHRM2
4 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.32 CHRM3 CHRM2
5 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.16 CHRM3 CHRM2
6 adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway GO:0007197 8.96 CHRM3 CHRM2
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 8.8 CHRM3 CHRM2 ADRB3

Molecular functions related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphoric diester hydrolase activity GO:0008081 9.26 PDE7A PDE5A
2 G protein-coupled serotonin receptor activity GO:0004993 9.16 CHRM3 CHRM2
3 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 8.96 PDE7A PDE5A
4 G protein-coupled acetylcholine receptor activity GO:0016907 8.62 CHRM3 CHRM2

Sources for Low Compliance Bladder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....